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Statistical Problems in Epidemiologic
Studies of the Natural History of Disease
by Ron Brookmeyer*
The development ofeffective disease prevention and treatment programs depends on an understanding
of the natural history of disease. A conceptual framework is presented for disease natural history and
consists of an asymptomatic period of disease followed by a period of symptomatic disease. The focus is
on epidemiologic studies for identifying risk factors ofthe onset ofasymptomatic disease, for identifying
cofactors of progression to symptomatic disease, and for estimating the duration of the asymptomatic
period. The strengths and limitations ofvarious epidemiologic study designs and sources ofepidemiologic
data are considered for characterizing disease natural history. Issues in the interpretation and analysis
of natural history parameters of disease estimated from cross-sectional, prevalent cohort, cohort, and
matched case-control studies are considered. The issues and analytic methods are illustrated with studies
ofthe acquired immunodeficiency syndrome (AIDS) andcervical cancer. Based onthese analytic methods,
an estimate ofthe incubation period distribution ofAIDS is given.
Introduction
An understanding ofthe natural history ofdisease is
important for developing effective disease prevention
and treatment programs. The objective ofthis paper is
to consider the strengths and limitations ofvarious ep-
idemiologic study designs and sources of epidemiologic
data for characterizing the natural history of disease.
A simple conceptual framework for the natural his-
tory of a disease is a two-stage model (Fig. 1). An in-
dividual is free of disease (healthy) until the onset of
stage 1 disease. Stage 1 refers to preclinical or asymp-
tomatic disease. It is assumed there is a diagnostic
screening test that can detect the presence of stage 1
disease. The individual with stage 1 disease may even-
tually progress to stage 2, which is the clinical or symp-
tomatic period. It is assumed that individuals enter
stage 1 before the onset of stage 2 disease. The focus
of this paper is on the natural history of disease up to
the onset of symptomatic disease (stage 2).
Two types of covariates affect the natural history of
disease. The first type, X1, are those that affect the risk
ofstage 1 disease. The hazard (or incidence) ofonset of
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FIGURE 1. Two-stage modelfordisease naturalhistory. Covariates,
X1, effect risk ofstage 1 (asymptomatic) disease. Covariates, X2,
effect risk of progression to stage 2 (symptomatic) disease.
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stage 1 at time s is call X(s; X1), where the time scale
smayrefereitherto calendartime orchronological age.
The second type ofcovariates, X12, are those that effect
risk ofprogression to stage 2 from stage 1 disease. The
duration of time spent in stage 1 has been termed the
preclinical duration, the incubation period and the so-
journ time (1). The distribution function of stage 1 du-
rations, F(t; X2), is the probability an individual with
stage 1 disease progresses to stage 2 within t years of
onset ofstage 1. The corresponding hazard and density
functions are called h(t; X2) and f(t; X2), respectively.
The distribution function may be improper as not all
individuals may eventually progress to stage 2.
Two examples illustrate this conceptual framework:
cervical cancer and the acquired immunodeficiency syn-
drome (AIDS). The natural history of cervical cancer
consists a very long asymptomatic period (stage 1),
which may consist ofhistological abnormalities ranging
from cervical intraepithelial neoplasia (CIN I, II, and
III) to preclinical invasive disease (2). The asympto-
matic period may be followed by the onset ofsymptoms
(stage 2) by which point the lesion has become invasive
cancer. Cervical cytology (the PAP test) can detect the
presence ofstage 1 disease. Riskfactors(X1)whichmay
be related to risk ofstage 1 disease include human pap-
illomavirus (HPV) infection and certain contraceptive
practices. A cofactor, X2 which has been suggested to
possibly accelerate progression to stage 2 from stage 1,
is infection with HPV Type 18 (3).
The natural history of AIDS begins with infection
with the etiologic agent, the human immunodeficiency
virus (HIV) (4,5). In our framework, the onset ofstage
1 refers to HIV infection (actually the development ofR. BROOKMEYER
HIV antibodies or seroconversion) while stage 2 refers
to clinically defined AIDS. The screening test for de-
tectingstage 1 istheAIDSantibodytest(ElisaorWest-
ernBlot). Riskfactors (X)forinfection (stage 1)include
high-risk behaviors (such as intravenous drug use and
large numbers ofsexualpartners), hemophilia, and pre-
vious blood transfusions. It has been suggested that a
cofactor (X2) for progression to clinical AIDS from the
asymptomatic HIV infected state is age at infection (6).
There are important public health reasons for study-
ing the natural history ofdisease. Identification ofrisk
factors for stage 1 disease is crucial for developing ef-
fective prevention programs. Identification ofcofactors
for progression to stage 2 is important for the devel-
opment of treatment and intervention programs: indi-
viduals at higher risk ofprogression to stage 2 may be
monitored more closely or treated more aggressively.
An estimate ofthe distribution function F(t; XC2) is im-
portant for two reasons. First, it is useful in developing
recommendations on screening frequency and the time
interval between screens; second, it is useful for pre-
dicting future cases of clinical disease. For example,
assumethatthetime ofonsetofstage 1 andthe duration
spent in stage 1 are independent given the covariates
X1 and X2. Then the cumulative probability an individ-
ual with covariates (X, X) develops stage 2 disease at
or before calendar time (or chronological age) t is
t
D(t; IS, I2) = f g(s; Xi)F(t - S; X2)ds (1)
whereg(s;IC,) = X(s;XI1)exp[ - X(s;Xl)ds]istheprob-
ability density ofonset ofstage 1 at time s. Eq. (1) has
been used to project the course of the AIDS epidemic
(7-9). Inforrnation is available both on the numbers of
AIDS cases diagnosed over calendar time and F(t) (the
incubation period distribution). Thus estimates of the
numbers of individuals previously infected can be ob-
tained through the technique of back-calculation (8).
These numbers infected are then projected forward to
obtain short-term projections ofAIDS incidence.
Epidemiologic Study Designs for
Characterizing Natural History
It is useful to consider the ideal epidemiologic study
for characterizing the natural history of disease. The
idealstudywouldconsist ofadisease-free cohortdefined
at (chronological or calendar) time s = 0. The cohort
would undergo continuous surveillance and screeningin
order to determine the exact times that individuals de-
velop stage 1 and stage 2 disease. The covariates X1
and X2 would be ascertained on all individuals. The
screening test to detect stage 1 disease would haveneg-
ligible error (specificity = sensitivity = 1.0). Further,
individuals detected in stage 1 would be monitored for
onset of stage 2. There would be no treatment inter-
ventionforthese individuals that could alterthenatural
history.
However, such a study is usually impossible to per-
form for many reasons. First, ifan effective treatment
exists, individuals detected with stage 1 must be
treated, which interrupts the natural history ofdisease.
Second, we cannot perform continuous screening tests
for stage 1 disease but, at best, perform only periodic
screens. Third, theerrors associated withthe screening
test may not be negligible. Fourth, a very large cohort
would be required for arare disease in orderto identify
a sufficient number ofindividuals with incident stage 1
disease. Fifth, the follow-up period would need to be
long for diseases with long incubation periods (stage 1
durations).
In the next sections, we consider the strengths and
limitations ofalternativeepidemiologicdesigns forchar-
acterizing the natural history of disease. We outline
analytic approaches to estimate parameters that de-
scribe disease natural history. We assume in the next
sections that the errors associated with the screening
test are negligible and can be ignored, although in the
last section, some consideration is given to situations in
which screening test errors are not negligible.
The Cross-Sectional Study
One of the simplest study designs is the cross-sec-
tional study. Consider a large cohort ofindividuals de-
fined at time s = 0. A random sample ofthese individ-
uals is chosen at a point in time (s = Y). We test each
individual in the sample for presence ofstage 1 disease
and obtain information on a covariate, Z. We assume,
for simplicity, Z is dichotomous. A common practice is
to cross classify individuals according to presence or
absence of stage 1 disease and the two levels of the
covariate (Z = 0 and Z = 1). This was the design ofa
recent study to investigate the relationship between
HPV infection and early stages ofcervical cancer (10).
What are the limitations ofthe cross-sectionalstudy for
characterizing natural history?
The most serious limitation is that the time sequence
of events cannot be established. We cannot determine
if an individual was exposed (Z = 1) before or after
onset ofstage 1 disease. This is an important limitation
with cross-sectional studies ofHPV infection and cerv-
ical cancer, because individuals with stage 1 (CIN) dis-
ease may be more (or perhaps less) prone to acquire
HPV infection. This problem is not unique to the cross-
sectional study and occurs in the case-control study as
well.
The issue ofthe time sequence does not arise ifZ is
a fixed covariate, that is, the value of the covariate is
determined at time s = 0 foreach individual. However,
even ifZ is afixed covariate, the interpretation ofcom-
monly used parameters of association such as the odds
ratio must be modified.
Table 1 displays the classification probabilities asso-
ciatedwiththe.2 x 2tablewhichresultsfromthe cross-
sectionalstudy, thatis, thejointprobabilitydistribution
of stage 1 disease (presence or absence) and the cov-
ariate value (Z = 0 or Z = 1). These probabilities
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depend onthefollowing:theincidenceofstage 1 disease,
X(s; Z); the distribution of stage 1 durations, F(t; Z);
the probability distribution ofthe covariate Z [i.e., P(Z
= 1) = p and P(Z = 0) = 1 - p)]; and the time s =
Ythat the cross-sectional study is conducted. The odds
ratio is the cross product ofthese cell probabilities, and
is independent of p. Under the assumption that stage
1 disease is rare with constant incidence rate, that is
Xl(s; Z) = exp(oto + a1Z), then the hazard XI(s; Z) is
approximately the density of g(s; Z). The odds ratio
from the cross-sectional study, WMC8 is approximately
eY
J (1 - F(t; Z = 1))dt
(1)8 exp (oal)C
-|(1 - F(t; Z = 0))dt-
Jo
For example, if the distribution of stage 1 durations is
exponential, namelyF(t) = 1 - exp( -exp(po + P3Z)t),
then
1e- eY-exp(130+31
WCS exp(ot, Y -e-exp(o)
If the study is conducted at a time s = Y sufficiently
large so that then the term in brackets in Eq. (2) is
nearly 1, then
IC8--exp(ao (3)
Under the above assumptions for which Eq. (3) is valid,
consider the following example: suppose an individual
with Z = 1 is at twice the risk of stage 1 disease [i.e.,
(eal = 2)]; further, suppose that amongthosewithstage
1 disease an individual with Z = 1 is at twice the risk
ofprogression to stage 2 disease (ef3 = 2.0). Using Eq.
(3), the odds ratio obtained from a cross-sectional study
(aside from sampling variation) would be 1.0. The naive
oddsratioobtained fromthecross-sectionalstudywould
suggest the covariate Z is not associated with disease,
when in fact, it is positively associated with both inci-
dence of stage 1 disease and progression to stage 2
disease.
In summary, the odds ratio obtained from the cross-
sectional study is determined by thejoint effects ofthe
covariate on both the risk of stage 1 disease and the
risk ofprogression to stage 2 disease. It is not possible
to separate out these effects solely from cross-sectional
data.
It may be possible to separate the effects with some
additional information. For example, we could supple-
ment the cross-sectional study with an incident case-
control study. The case-control study would consist of
incident cases of stage 2 disease and a sample of con-
trols. Covariate information, Z, would be ascertained
on all cases and controls. Under the same assumptions
which led to Eq. (3), the odds ratio from the incident
case-control study would be (aside from sampling var-
iation)
W : e'l .
Then the ratio of the odds ratios obtained from the
incident case-control and cross-sectional studies is wj/ ()C8
= e1l. Thus, in this case, the supplementary data
allows separate estimation of the two effects, eal and
el.
The Prevalent Cohort Study
The prevalent cohort study consists of a cohort of
individuals, each ofwhom has stage 1 disease at entry
intothecohort. Thepriortimeofonsetofstage 1 disease
is a random, unknown quantity. The cohort is followed
for onset ofstage 2 disease. The objective is to identify
cofactors, X2, of disease progression and to estimate
F(t; X2). This design was recently used in several nat-
ural history studies of the acquired immunodeficiency
syndrome, in which patients with prevalent HIV infec-
tion were enrolled in a cohort and followed for onset of
clinical AIDS.
The prevalent cohort study has advantages but also
serious limitations. One advantage is that it is not nec-
essarytofollow alargecohortofdisease-free individuals
in order to identify incident (newly onset) stage 1 dis-
ease. Rather, individuals identifiedwithprevalentstage
1 diseasefrom across-sectional surveycouldbeenrolled
into the cohort. The savings in terms ofsample size and
follow-up time could be substantialifthe disease is rare,
(i.e., X(s;X1) is small). However, the fact that individ-
uals with prevalent stage 1 disease are enrolled in the
cohort rather than incident stage 1 disease is also a
serious limitation. There are biases inherent in esti-
matingtherelativeriskofacofactorandthedistribution
function F(t; XC2) from prevalent cohorts (11).
For example, let F*(t, X2) be the cumulative proba-
bility ofonset ofstage 2 disease within t years offollow-
up for an individual prevalent with stage 1 disease at
the beginning offollow-up. In general F*(t, X2) wil not
equalF(t; XC2). The direction ofthe bias (F*(t; X2) -F(t;
X2)), depends on whether the hazard, h(t; I2) ofonset
of stage 2 disease t years after entering stage 1 is in-
creasing or decreasing. Ifthe hazard is increasing then
F*(t; XI2) > F(t; IX2). The intuition for this result is that
with an increasing hazard of onset of stage 2, an indi-
vidual with prevalent stage 1 disease has a worse prog-
Table 1. Classification probabilities in a cross-sectional study conducted at time 8 = y.a
Stage 1 disease Disease-free
Z = 1 p.fy * g(s;Z = 1) [1 - F (Y - s; Z = 1] ds p*exp (- fy A (s; Z = 1)ds
Z = 0 (1 - p)fIYg(s; Z = 0) [1 - F (Y - s; Z = 0] ds (1 - p) * exp (- fy A (s; Z = O) ds
aThe covariate Z is dichotomous taking values 0 and 1 withprobabilities (1 - p) and p, respectively.
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nosis than an individual with newly onset stage 1 dis-
ease, because the prevalent individual has had stage 1
disease for a longer period of time. The bias can be
substantial. Forexample, an estimate ofthe cumulative
probability ofdeveloping AIDS within 3 years offollow-
up based on a prevalent cohort, was 0.34 (12). More
recent estimates based on cohorts ofnewly infected in-
dividuals suggestthiscumulative probabilityislessthan
0.05 (6,13).
Assuming a proportional hazards model h(t) =
hO(t)exp(13Z) where t is the time since onset of stage 1
disease, then estimates of the relative risk exp(,B) de-
rived from a prevalent cohort will be biased ifthe pro-
portional hazards analysis is performed using follow-up
time. There are two reasons for the bias. The first rea-
son is that the distribution of the prior times of onset
of stage 1 disease for two subgroups (Z = 0 and Z =
1) may be different (X(s; Z = 0) * X(s; Z = 1). For
example, one prevalent cohort study reported a higher
cumulative proportion of AIDS in New York than in
Washington (12). The most plausible explanation is the
New York cohort was infected earlier in calendar time
than the Washington cohort, and not that geography is
a cofactor ofdisease progression. The second reason for
bias occurs even ifX(s; Z = 0) = X(s; Z = 1). This bias
is due to the differential effects of length-biased sam-
pling in the two subgroups (Z = 0 and Z = 1). The
direction ofthe bias alsodepends onwhetherthe hazard
h(t) increases or decreases over time. For example, if
Z is areal cofactor (I > 0) and the hazard is increasing,
then the individuals with Z = 0 will tend to have been
in stage 1 longer at the beginning of follow-up then
individuals with Z = 1. This biases the relative risk 13
toward unity. Fortunately, as shown in Brookmeyer
and Gail (11) this bias is not of sufficient magnitude to
reverse the direction of an effect [that is, make a real
cofactor (,B > 0) appear protective].
Cohort Studies of Serially Screened
Populations without Treatment
Intervention
Inthis section, we considercohort studies ofaserially
screened population without treatment intervention.
Suppose a cohort of disease-free individuals is defined
at calendar time (or chronological age) s = 0. Individ-
uals in the cohort are periodically screened for presence
or absence of stage 1 disease. All individuals are fol-
lowed for onset of stage 2 disease. It is assumed there
is no treatment intervention for individuals detected
with stage 1 disease and, further, the errors associated
with the screening test are negligible. Then, it is pos-
sible to determine the onset time of stage 1 disease up
to an interval. This type ofstudyhas considerably more
information than either the cross-sectional or prevalent
cohort study. Unlike the cross-sectional and prevalent
cohort study, this design allows estimation of the sep-
arate effects of a covariate on risk of stage 1 disease
and risk of progression to stage 2 from stage 1.
This was the design of a recent epidemiologic study
ofthe naturalhistory ofAIDS amonghemophiliacs (14),
the National Cancer Institute Multicenter Hemophilia
Cohort Study. Hemophiliacs were at risk ofHIV infec-
tion from the mid-1970s in the United States because
of contamination of replacement clotting factors. The
study consisted of hemophiliacs who regularly visited
treatment centers. Serumsampleswhichwere obtained
at these visits were stored and subsequently tested for
presence ofHIV infection. The following information is
recorded on each individual (the subscript i denotes in-
formation obtained from the ith individual): a) an in-
dicator variable E that indicates whetherthe individual
had a positive screening test during follow-up (in which
case we set Ei = 1, or otherwise Ei = 0); b) if the in-
dividual had a positive test, then the interval in which
onset ofstage 1 disease occurred is recorded as (Li, Ri)
where Li is the calendar (or chronological age) time of
the most recent negative test andRi is the calendar (or
chronological age) time ofthe earliestpositive screening
test; c) an indicator, bi, that indicates if the individual
had onset ofstage 2 disease by last follow-up (in which
case bi = 1 or otherwise bi = 0); d) the time ti of last
follow-up or onset of stage 2 disease whichever comes
first; and e) covariates X1i and X2i. The analysis must
account for the fact that the time ofinfection is known
only up to an interval.
Weassumeindependencebetweenonsettimeofstage
1 and the duration spent in stage 1 conditionally on the
covariates X1 and X2. Assuming parametric models for
the probability density functions ofstage 1 disease, g(s;
IC) and stage 2 disease,fit, X2), the full likelihood func-
tion can be derived. Each individual contributes one of
four possible factors to the likelihood, corresponding to
thefourvaluesof(Ei, bi). Thesefactorscanbeexpressed
in terms of convolutions. For example, the likelihood
contribution for an individual with -i = 1 and bi = 1 is
JRi
g(s; Yl)f(ti - s; X2)ds (4)
Brookmeyer and Goedert describe this approach (14).
Modified Newton-Raphson algorithms can be used to
find the maximum likelihood estimates of the parame-
ters of the stage 1 and stage 2 disease incidence func-
tions. The analysis produces not only estimates of rel-
ative risk of covariates but also estimates of the
incubation period distribution, F(t; X2). The analysis
(14) ofthe National Cancer Institute Multicenter Hem-
ophilia Cohort Study found that age was a cofactor (X2)
of disease progression. Table 2 gives the estimates of
F(t) for hemophiliacs over the age of 20. The estimate
of the 3-year cumulative probability of AIDS was only
0.033, which is considerably less than prior estimates
obtained from prevalent cohorts.
Cohort Studies of Serially Screened
Populations with Treatment Intervention
A major analytic complication ofmost cohort studies
of disease natural history is that if an effective treat-
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Table 2. Estimated cumulative probability ofAIDS within t
years of seroconversion, F (t), and 95% confidence intervals for
individuals over age 20 based on hemophilia cohort.
t years F (t) 95% Confidence intervala
1 0.002 (0.002, 0.006)
2 0.012 (0.011, 0.024)
3 0.033 (0.025, 0.065)
4 0.066 (0.045, 0.095)
5 0.113 (0.088, 0.168)
6 0.174 (0.128, 0.238)
7 0.245 (0.180, 0.320)
aConfidence intervals computed for each fixed t separately by in-
version of a likelihood ratio test.
ment exits, then individuals who are detected in an
asymptomatic state (stage 1) must be treated. Consider
a cohort of disease-free individuals defined at calendar
time (or chronological age) s = 0. Individuals are pe-
riodically screened for stage 1 disease. If an individual
is detected with stage 1 then he is treated. At the time
treatment begins, the individual no longer contributes
information about natural history because the natural
course of the disease is altered.
Assumingparametricmodelsforthestage 1 and stage
2 disease incidence functions, the fulllikelihood function
canbe developedunderthe assumption ofindependence
between onset time and duration ofstage 1 disease. In
the notation of the preceding section, individuals con-
tribute one of three possible factors to the likelihood
corresponding to (ei = 1), (Ei = 0, bi = 0), and (Ei =
0, bi = 1). For example, the likelihood contribution for
an individual detected with stage 1 disease (Ei = 1) at
time Ri is Eq. (4) with the stage 2 probability density
functionf(t; X2) replaced by the survival function 1 -
F(t; XC2). The stage 1 durations for individuals detected
by the screen (Ei = 1) are right censored because of
treatment intervention. Accordingly, important infor-
mation for estimating the parameters ofF(tj X2) is de-
rived from individuals with onset of both stage 1 and
stage 2 disease between two successive screening tests
(Ei = 0, 8i = 1).
Under a rare disease assumption with constant inci-
dence of stage 1 disease, X(s; X1) = exp(ao + o1X),
an approximate Poisson likelihood can be constructed
as in Day and Walter (15). Suppose the screening tests
occur at fixed times Si, S2,... ,Sk for all individuals.
Then the number ofindividuals, di, who are diagnosed
with stage 2 disease between the ith and (i +1)St screen
has an approximate Poisson distribution with mean
eao + alXl F(si+1 -si)
The numberofindividuals detected with stage 1 disease
at the ith screen is also approximately Poisson distrib-
uted with mean
Si-Si-i
eao + alXl [1 -F(u)]du
0
Amodification ofthis approach has been used in abreast
screening program (1,15) to account for errors in the
screening test.
Case-Control Studies of Serially Screened
Populations with Treatment Intervention
There are a number of disadvantages of the cohort
study described in the preceding section. Ifthe disease
is rare (X(s; IC) small) a very large cohort would be
required and the screening program would have to be
centrally organized. An alternative design is the case-
control study. The advantage, ofcourse, is follow-up on
a large cohort is not required. However, an important
limitation ofthe case-control design is that the absolute
incidence of stage 1 is not estimable because the num-
bers of cases that are sampled are pre-fixed. Never-
theless, the case-control approach canbe useful, and we
briefly consider analytic approaches for gleaning infor-
mation about natural history from matched case-control
studies.
In case-control studies of a serially screened popu-
lation, there are two types of cases. The first type is
cases with incident stage 2 disease, and the second type
are cases that are screen detected with stage 1 disease.
Cases that are diagnosed between screens withincident
stage 2 disease are called interval cases to emphasize
that the cases are diagnosed in the interval between
screens. Casesdetectedbythescreeningtestwithstage
1 disease are called screendetected cases. Eachinterval
case is matched to R controls on the basis of specified
matching criteria (R may vary across matched sets).
These controls are required to be free ofstage 2 disease
at the time of diagnosis of the case. Each screen de-
tected case is alsomatchedtoR controls. These controls
are required to have screened negative at the time the
screen detected case was found with stage 1 disease.
We assume an underlying cohort defined as s = 0.
Individuals are screened at random times, beginning at
some sufficiently large time, s*, so that F(s*) = 1.
We assume stage 1 disease is rare with constant in-
cidence rate. We allow for the fact that the incidence
of stage 1 disease may depend upon covariates not in-
cluded in the matching criteria. We assume the inci-
dence ofstage 1 disease for thejth individual in the ith
matched set with covariate vector Xij is Xij =
Xiexp(q1ij). In this model, we are allowing for the pos-
sibility that the baseline incidence of stage 1 disease,
Xi, may vary across matched sets. The covariate vector,
Xij, includes covariates that are not included in the
matchingcriteriathateffectincidenceofstage 1 disease.
It is further assumed for simplicity that there is a com-
mon distribution function of stage 1 durations, F(t),
which does not depend on any covariate. The time in-
terval between selection as a case or control and the
last prior screening test is ascertained and is called tij,
where i indexes the matched set and j = O, ... ,R in-
dexes the individuals in the set. By convention we let
j = 0 refer to the case. Ifthe individual did not have a
prior screen we set tij = +oo°
We assume a parametric model for F(t) and that F is
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a proper distribution function; that is we assume a pro-
gressive disease model. We can construct a conditional
likelihood (16,17) that involves the parameters a and
the parameters ofF(t). Matched sets (based on interval
cases) contribute the following factor to the conditional
likelihood
e-xioF(tio) R ~~~~~~~~~(5) R
I eCXXijF(tjj)
j=o
We note the term Xi appears in the numerator and de-
nominator of Eq. (5) and cancels out. Matched sets
based on screen detected cases contribute analogous
contributions as Eq. (5) exceptFis replaced byFB, the
backward recurrence time distribution
l st
FB(t) =- (1 - F(u))du
where ,u =f(1- F(u))du is the expected stage 1
duration. The backward recurrence time distribution is
the distribution function of durations spent in stage 1
for an individual who is known to be prevalent with
stage 1 disease at a fixed point in time. The conditional
maximum likelihood estimates are found by maximizing
the product ofthe likelihood contributions from the in-
terval and screen-detected matched sets. The condi-
tional likelihood is independent of the parameters Xi,
the baseline incidence of stage 1 disease in the ith
matched set. This serves to emphasize again that it is
not possible to estimate absolute incidence from a case-
control study.
A modification ofthis analytic approach was used in
the analysis of a matched case-control study of PAP
smear screening for cervical cancer in Northeast Scot-
land (17). The modification accounted for screening test
errors, and also accounted for the fact that not all pre-
clinical lesions (stage 1 disease) progress to clinically
(symptomatic) invasive cervical cancer (stage 2).
Errors in the Screening Test
We have considered the strengths, limitations, and
analytic approaches associated with various epidemio-
logic designs for studies ofdisease natural history. An
underlying assumption of the preceding sections was
that diagnostic errors of the screening test were neg-
ligible and could be ignored. Often the test errors are
not negligible; thus, the analytic approaches must be
modified accordingly. There are two types of errors.
The false positive error occurs when anindividual with-
out stage 1 disease falsely tests positive. The false neg-
ative error occurs when an individual with stage 1 dis-
ease falsely tests negative.
In order to develop analytic procedures in the pres-
ence oftest errors, additional probabilistic assumptions
are required. For example, one can assume the prob-
ability ofa false positive error is 0, the probability ofa
false negative error is E, and further errors on succes-
sive screens are independent. These were the assump-
tions employed in an analysis ofnatural history from a
breastcancerscreeningprogram(15) and acervicalcan-
cer screening program (16).
An alternative to the independence assumption is to
assume a proportion ofindividuals with stage 1 disease
always falsely test negative. Another alternative is to
assumethe probability ofafalse negativeerrorchanges
over the course of stage 1 disease. For example, the
preclinical stage (stage 1) of cervical cancer can be di-
vided into a noninvasive preclinical disease phase and
an invasive preclinical disease phase. One can assume
thatthe false negative probabilities are differentforthe
two phases and that test errors conditional of the dis-
ease state (i.e., precinical noninvasive or preclinical
invasive) are independent.
Under model assumptions for test errors such as
those described above, the likelihood function for the
various epidemiologic designs could be derived. The
likelihood function would include an additional param-
eter, E, which is the probability offalse negative error.
This parameter can be estimated jointly along with the
other natural history parameters (1,17). However, an
important caveat is that parameter estimates may be
highly correlated. For example, under the indepen-
dence assumption it was found that the estimate of e,
theprobabilityofafalsenegativeerror, and ,u, themean
stage 1 duration, were highly correlated (15). Clearly,
itwouldbepreferabletouseareliable externalestimate
ofE, ifavailable, rather than tojointly estimate E along
with the other natural history parameters.
However, even if an estimate of e was available, as-
sumptions aboutthejoint distribution ofsuccessive test
results, conditional on the true disease state, would be
required. An important issue in studies of disease nat-
ural history concerns the development of plausible as-
sumptions about screening test errors and the sensitiv-
ity of estimates of natural history parameters to
alternative model assumptions about these errors.
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